Table 4 COVID-19 treatments after COVID-19 diagnosis (propensity score–matched study cohorts)
Treatment, n (%)a | Nonallergic asthma (n = 1578) | Allergic asthma (n = 1578) | P valueb |
|---|---|---|---|
Any | 561 (35.6) | 509 (32.3) | 0.0505b |
Hydroxychloroquine/chloroquine | 59 (3.7) | 58 (3.7) | 0.9249b |
Dexamethasone | 334 (21.2) | 274 (17.4) | 0.0068b |
Methylprednisolone | 291 (18.4) | 281 (17.8) | 0.644b |
Remdesivir | 119 (7.5) | 103 (6.5) | 0.2654b |
Tocilizumab | 16 (1.0) | 13 (0.8) | 0.5757b |
No. of treatmentsc | Â | 0.2473 | |
  0 | 1017 (64.5) | 1069 (67.7) | |
  1 | 354 (22.4) | 329 (20.8) | |
  2 | 145 (9.2) | 135 (8.6) | |
  3 | 57 (3.6) | 40 (2.5) | |
  4 | 5 (0.3) | 4 (0.3) | |
  5 | 0 | 1 (0.1) | |